Two studies were conducted to further assess its mutagenic and genotoxic potential. In a bacterial reverse mutation pre-incubation study, Salmonella typhimurium strains TA100, TA1535, TA98, and TA1537 and Escherichia coli WP2 uvrA were treated with aspartame at concentrations of up to 5000 μg/plate with or without metabolic activation and showed no mutagenic potential. Similarly, in vivo micronucleus testing of aspartame following gavage administration (500-2000 mg/kg body weight) to Crlj:CD1(ICR) strain SPF male mice showed no increase in the proportion of micronucleated polychromatic erythrocytes in bone marrow cells collected and evaluated 24 or 48 h post administration. Overall, aspartame had no potential for mutagenic or genotoxic activity.
Introduction
Aspartame, a non-nutritive intense sweetener that is approximately 200 times sweeter than sucrose, is an alpha methyl ester of a dipeptide comprised of aspartic acid and phenylalanine. Aspartame is approved for use in a wide range of food products in more than 90 countries around the world. Its safety has been evaluated by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), as well as by numerous national food safety authorities, including the US Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA) (JECFA, 1981; US FDA, 1996; EFSA, 2013) . Magnuson et al. (2007) specifically reviewed the carcinogenicity of aspartame, and it has been the subject of extensive regulatory scrutiny. In addition, Kirkland and Gatehouse (2015) recently published an extensive review of the available in vitro and in vivo genotoxicity data of aspartame in 2015. The purpose of the review was to critically assess the available literature on the potential genotoxicity of aspartame and provide a detailed description of the available studies. The authors concluded that there was no evidence of mutagenic activity in bacterial systems and the weightof-evidence (in vivo bone marrow micronucleus, chromosomal aberration, and Comet assays) with in vivo somatic cell systems shows no genotoxic potential indicating that, overall, aspartame is non-genotoxic.
While the available evidence indicates that aspartame is without genotoxic potential, data generated from Good Laboratory Practice (GLP)-and Organisation for Economic Co-operation and Development (OECD)-or FDA Redbook-compliant studies are not completely available in the public domain outside of summary discussion in review and regulatory publications cited above. Also, since the time when these genotoxicity data were first generated in support of the safety and registration of aspartame as a food additive, the testing guidelines for conduct of these assays have undergone significant changes.
In addition to the relative scarcity of published detailed genotoxicity studies carried out under GLP conditions at recognized FDA inspected Contract Research Organizations (CROs), the recent reviews of EFSA (2013) and Kirkland and Gatehouse (2015) discuss a number of studies in which "positive" results were reported both in vitro (Rencüzoğullari et al., 2004) and in vivo (Bandyopadhyay et al., 2008; AlSuhaibani, 2010; Kamath et al., 2010) . These studies were not conducted under GLP-conditions, and EFSA (2013) found multiple deficiencies limiting their usefulness in determining the genotoxic potential of aspartame. In particular, the in vivo mouse micronucleus assay reported on by Kamath et al. (2010) provided a pattern of response difficult to explain (i.e., higher micronucleus response in peripheral blood versus bone marrow at 24 h despite the fact that micronucleated cells induced in bone marrow do not appear in blood until much later) (Kirkland and Gatehouse, 2015) . Despite the limitations in design, conduct and interpretation of published studies that have reported "positive" genotoxic effects, such studies continue to be cited to infer that exposure to aspartame through use as a high intensity sweetener poses a genotoxic risk (Yulmaz and Uçar, 2014) .
Limitations have also been noted in the published "negative" Ames studies (Molinary, 1978; Rencüzoğullari et al., 2004; NTP, 2005; Bandyopadhyay et al., 2008) , namely that they did not include bacterial strains (i.e., either S. typhimurium TA102 or E. coli WP2 uvrA) optimized to detect mutagens which act at adenine-thymine base pairs (Kirkland and Gatehouse, 2015) ; hence this potential mode of mutagenic action for aspartame has not been adequately assessed.
Given the preceding as a backdrop, and the controversy that had been raised by the results of carcinogenicity studies conducted by the Ramazzini Institute in rats Soffritti et al., 2006 Soffritti et al., , 2007 and mice (Soffritti et al., 2010) , even though these studies were found to be seriously flawed by regulatory agencies and others (EFSA, 2006 (EFSA, , 2013 Gift et al., 2013) , experiments were conducted to specifically address the potential short-comings of previously conducted Ames assays and to further assess the significance of the findings of "positive" results in in vivo micronucleus and/or chromosome aberration assays previously reviewed by EFSA (2013) and Kirkland and Gatehouse (2015) .
In the present experiments, the potential mutagenicity and genotoxicity of aspartame was re-examined in a bacterial reverse mutation study conducted in several Salmonella typhimurium strains and in Escherichia coli WP2 uvrA (a strain that detects effects on A-T base pairs) in the presence or absence of metabolic activation. In addition, an in vivo murine micronucleus test was conducted in which the bone marrow of treated male mice was collected and then evaluated for the potential to induce micronucleated polychromatic erythrocytes (MNPCE). Both studies were conducted under GLP conditions and to the standards of the FDA Redbook 2000 (US FDA, 2000a,b) . The Ames assay was also conducted to the latest OECD Test Guideline (OECD TG 471) while the in vivo micronucleus study was conducted in general accordance with OECD TG 474, except for the fact that 2000 polychromatic erythrocytes (PCE) per animal were scored as opposed to the recommended 4000 as stated in the most recent version of these guidelines (OECD, 2016) . The previous 1997 OECD Guidelines recommended 2000 PCE per animal), the standard to which the current test was conducted. .
Materials and methods

Test article
The aspartame used in these studies was supplied by Ajinomoto Co., Inc. as white crystals at a purity level of 99.5% and was dissolved in dimethyl sulfoxide (DMSO) or carboxymethylcellulose sodium (CMCNa) for the bacterial reverse mutation test or the micronucleus test, respectively, in order to prepare the appropriate testing concentrations.
Bacterial reverse mutation study
This study was conducted at Bozo Research Center Inc., Tokyo, Japan in compliance with the Japanese Ministry of Health, Labor and Welfare Good Laboratory Practice (GLP) standards (MHLW, 2008a,b) and in accordance with the testing guidelines of the FDA Redbook 2000 (US FDA, 2000b).
Test system
The tester strains used were S. typhimurium TA100, TA1535, TA98, and TA1537 and E. coli WP2 uvrA and were obtained from the Division of Genetics and Mutagenesis, National Institute of Health Sciences by Gotemba Laboratory, Bozo Research Center Inc. Twenty microliters (20 μl) of each S. typhimurium strain or 10 μl of E. coli strain bacteria, were seeded to an L-shaped tube containing 10 mL of culture medium. The culture was set in a thermostatically controlled bath shaker (ML-10 Cool Bath Shaker with PU-6, Taitec Corporation), maintained at 4°C for 6.5 h, and then pre-cultured while shaking at 100 rpm for 9 h at 37°C. At the end of pre-culturing, absorbance was measured by a spectrophotometer (Mini photo 518R, Taitec Corporation) and the level of acceptance for the converted number of bacteria was set at 1 × 10 9 cells/mL or higher. The bacterial solutions were allowed to stand at room temperature until use.
Preparation of S9 mix
The S9 (metabolic activation system purchased from Kikkoman Corporation) was prepared from phenobarbital/5,6-benzoflavone-induced male rats. The S9 mix was prepared in the testing laboratory by dissolving Cofactor-I (Oriental Yeast Co. Ltd.) in sterile purified water, filter-sterilizing the solution and then adding S9 after which the mixture was refrigerated until use. The final constituents of the S9 mix were 90% water, 10% S9, 8 μmol MgCl 2 /mL, 33 μmol KCl/mL, 5 μmol glucose-6-phosphate/mL, 4 μmol reduced nicotinamide adenine dinucleotide phosphate (NADPH)/mL, 4 μmol reduced nicotinamide adenine dinucleotide (NADH), and 100 μmol sodium phosphate buffer (pH 7.4)/ mL.
Positive controls
For cultures with metabolic activation, 2-aminoanthracene (Wako Pure Chemical Industries Ltd.) was used for strains TA1535 and WP2 uvrA at concentrations of 2.0 and 10.0 μg/plate, respectively, and benzo[a]pyrene (AccuStandard Inc.) was used for strains TA100, TA98, and TA1537 at a concentration of 5.0 μg/plate. For cultures without metabolic activation, 2-aminoanthracene (Wako Pure Chemical Industries Ltd.) was used for strains TA100, TA98, and WP2 uvrA at concentrations of 0.01, 0.1, and 0.01 μg/plate, respectively, sodium azide (Wako Pure Chemical Industries Ltd.) at a concentration of 0.5 μg/plate was used for strain TA1535, and 2-methoxy-6-chloro-9-[3-(2-chloroethyl)-aminopropylamino]acridine 2HCl (Polysciences Inc.) at a concentration of 1.0 μg/plate was used for strain TA1537. All positive controls were dissolved in DMSO with the exception of sodium azide, which was dissolved in water, and were stored at −20°C or below.
Preliminary range-finding test
A preliminary test at concentrations of 1.22, 4.88, 19.5, 78.1, 313, 1250, or 5000 μg aspartame/plate with or without metabolic activation was conducted to determine the appropriate concentration range for the main test and followed the same procedure as described below for the main test.
Main test
The test article, vehicle, and positive controls were exposed to the tester strains using the pre-incubation method (Ames et al., 1973; McCann et al., 1975; Green and Muriel, 1976; Maron and Ames, 1983 . Each culture was conducted in triplicate. Top agar containing 0.6% agar and 0.6% NaCl and supplemented with D-biotin, L-histidine solution and L-tryptophan solutions at concentrations of 0.5 mmol/L was prepared, then sterilized in an autoclave, microwaved prior to use, and maintained in a thermostatic chamber at 45°C. Nutrient broth No. 2 (OXOID Ltd.) was dissolved in purified water to make a 2.5% solution, sterilized in an autoclave, and refrigerated until use.
Test concentrations of 78.1, 156, 313, 625, 1250, 2500, and 500 μg aspartame/plate were used with or without metabolic activation in the main test. In sterilized test tubes, 0.1 mL of the test article solution, vehicle control, or positive control, 0.5 mL of 0.1 mol/L phosphate buffer (for cultures without metabolic activation) or 0.5 mL of S9 mix (for cultures with metabolic activation), and 0.1 mL of tester strain solution were added. After stirring, the test tubes were incubated at 37°C on a shaker at 80 rpm. After 20 min, 2.0 mL of molten top agar (45°C) was added to each tube, and this mixture was shaken and overlaid uniformly on minimal glucose agar plate medium (Kyokuto Pharmaceutical Industrial Co. Ltd.). Once the top agar was solidified, the minimal glucose agar plate medium was inverted and incubated at 37°C for 48 h. Since no precipitation or discoloration was observed at any concentration level with or without metabolic activation, the number of revertant colonies was counted with an automatic colony counter (Colony Analyzer CA-11D systems, System Science Co., Ltd.). A stereoscopic microscope was used to examine the presence or absence of growth inhibition.
To confirm the sterility of the S9 mix and the aspartame test solution, each solution was plated (0.5 mL aliquot for S9 mix and a 0.1 mL aliquot for the highest concentration of aspartame) after mixing with 2.0 mL of top agar on the minimal glucose agar plate medium.
Confirmation test
The test was repeated in S. typhimurium strains TA1535 (with S9) and TA98 (with and without S9) under the same conditions and at the same concentrations used in the main test with the exception that the cultures were incubated for 48.5 h instead of 48 h.
Evaluation of results
The mean and standard deviation of the number of revertants per plate were calculated. If a 2-fold or more increase in the number of revertant colonies to that of spontaneous revertant colonies (the vehicle control) and dose-response and reproducibility were noted, or even if no clear dose-response was observed but there was at least 2-fold increase in comparison with the number of spontaneous revertant colonies and reproducibility was observed in the main and confirmation tests, the test article was considered to be positive.
In vivo mouse micronucleus study
This study was conducted at Gotemba Laboratory, Bozo Research Center Inc., Shizuoka, Japan in compliance with the Japanese Ministry of Health, Labor and Welfare Good Laboratory Practice (GLP) standards (MHLW, 2008a,b) and in accordance with the testing guidelines of the FDA Redbook 2000 (US FDA, 2000a). Animals were humanely treated and cared for in accordance with Japanese regulations on animal welfare (MEJ, 2006; SCJ, 2006; JLHTMA, 2011) and the Animal Experiment Committee of the test facility approved the conduct of the study.
Animals
Sixty (60) 7-week-old Crlj:CD1(ICR) strain SPF male mice were obtained from Atsugi Breeding Center, Charles River Laboratories Japan Inc. and were acclimatized for 8 days. The mice were weighed (day of animal receipt, final day of acclimatization and day of group allocation) and observed for general condition once daily during the acclimatization period. Based on the results, healthy 8-week-old animals (54 animals for this study) were selected and using computer randomization based on body weight gain during the acclimatization period, the animals were allocated into the test groups. Individual body weight of the mice ranged from 31.9 to 38.8 g on the day of administration.
Animal husbandry and diet
Mice were individually housed in plastic cages at a room temperature of 21-23°C with a relative humidity of 50-59%, air cycle of 10-15 times/hour, and a 12 h/day illumination period. Pelleted diet (CRF-1; Oriental Yeast Co. Ltd.) and drinking water (Gotemba city water) were provided ad libitum.
Administration
The test article was weighed and mixed with an appropriate volume of vehicle (0.5% CMC-Na) to obtain the dose levels selected for the study. Dosing suspensions were stored at 5-7°C and used within 7 days of preparation. Mice (12/group) were administered a single dose of 0 (vehicle control), 500, 1000, or 2000 mg aspartame/kg body weight by gavage at a dose volume of 10 mL/kg body weight. The positive control group (6 mice) received a single dose of 1 mg mitomycin-C/kg body weight by gavage at a dose volume of 10 mL/kg body weight.
Clinical observations and body weight
Animals were observed for general condition (external appearance, nutritional condition, behavior, and excrement) before, immediately after, and approximately 2 h after dosing on the day of administration and once daily until euthanasia and bone marrow collection. Body weights were measured once daily on the day of administration and once daily until euthanasia and bone marrow collection.
Collection and preparation of bone marrow
Six animals of each group (except the positive control group) were euthanized by cervical dislocation at approximately 24 and 48 h after administration. The positive control group was euthanized at approximately 24 h after administration. Femoral bone marrow cells were collected and smear specimens prepared.
The femurs of both sides were removed and both ends of the femurs were cut off. Bone marrow cells were flushed out into a centrifuge tube containing approximately 0.1-0.2 mL of fetal bovine serum (GIBCO BRL) using a 1-mL injection syringe, centrifuged at 1000 rpm for 5 min, the supernatant was discarded, and the precipitate was agitated by using a mixer and then smeared on glass slides (1 smear specimen each was prepared for the right and left femurs per animal). The smeared cells were air-dried, fixed with methanol (Wako Pure Chemical Industries Ltd.) for 3 min and air-dried again. A cover glass on which 40 μg acridine orange solution/mL had been dropped in advance was placed on the slide. A label indicating the study number, stage, sample number, type of study and day of preparation was attached (blind method) to each specimen.
Scoring for micronuclei
Glass slides were viewed under a fluorescent microscope at a magnification of 600 times with light at wavelength of approximately 490 nm and observation filter that transmits the light of wavelength at 515 nm or longer. For each animal, the numbers of PCE and normochromatic erythrocytes per 1000 erythrocytes and the number of micronucleated polychromatic erythrocytes (MNPCE) per 2000 PCE were manually counted and their proportions (%) calculated.
Evaluation of results
The mean with standard deviation was calculated for the number and proportion (%) of MNPCE and the number and proportion (%) of PCE. For each proportion (%), the maximum and minimum values also were recorded.
To assess the significance of the proportion of micronuclei, it was confirmed that the proportion of MNPCE of the vehicle and positive control groups were within the mean ( ± 3 standard deviations) of the background data of the test facility. In addition, the vehicle control group and each test article administration group at each bone marrow collection time were compared using the Kastenbaum and Bowman test (Kastenbaum and Bowman, 1970 ) based on binominal distribution (5% level of significance, unilateral) and the Cochran-Armitage trend test (Cochran, 1954; Armitage, 1955 ) (1% and 5% levels of significance, bilateral). For the proportion of PCE, Bartlett's test (Bartlett, 1937 ) was used to examine homogeneity of variance (1% level of significance, bilateral) between the vehicle control group and each test article administration group at each bone marrow collection time. Since the variance was homogeneous, the Dunnett test (Dunnett, 1964) was conducted (1% and 5% levels of significance, bilateral).
Results
Bacterial reverse mutation study
Preliminary range-finding test
In the preliminary test, there was no precipitation, no discoloration by the test article, and no growth inhibition at any concentration level in any tester strain in the presence or absence of metabolic activation. No positive findings (i.e., 2-fold increase in the number of revertants per plate) were reported in S. typhimurium TA100 and TA1537 and in E. coli WP2 uvrA with or without metabolic activation and in S. typhimurium TA1535 without metabolic activation. However, a greater than 2-fold increase in the number of revertants per plate was reported in S. typhimurium TA98 with or without metabolic activation and in S. typhimurium TA1535 with metabolic activation (Table 1) . Therefore, for the main test the maximum concentration level was set at 5000 μg aspartame/plate for all the tester strains with or without metabolic activation.
Main test
No precipitation, no discoloration by the test article, and no growth inhibition at any concentration level in any tester strain in the presence or absence of metabolic activation was observed. There was no increase (2-fold or more) in the number of revertants per plate in any of the tester strains at any concentration level (Table 2) .
Confirmation test
To confirm that there was no increase in the number of revertants per plate as observed in the preliminary test, S. typhimurium TA98 with or without metabolic activation and S. typhimurium TA1535 with metabolic activation were re-tested. Similar to the preliminary and main tests, no precipitation, no discoloration by the test article, and no growth inhibition were noted. In addition, no increase (2-fold or more) in the number of revertants per plate was observed in the two tester strains (Table 3) confirming the finding in the main test.
In vivo mouse micronucleus study
The stability (24 h at room temperature and 8 days at 1-10°C), uniformity, and concentration of the dosing suspensions (104.0-105.4% of the nominal concentrations) were verified using high performance liquid chromatography (HPLC).
Clinical observations and body weight
There were no abnormal changes in clinical signs or body weight in any of the test groups (data not shown).
Bone marrow evaluation
There were no statistically significant differences in the number of MNPCE/2000 PCE, the proportion of MNPCE, the number of PCE/1000 erythrocytes, or the proportion of PCE in any of the aspartame-treated groups compared to vehicle control at 24 or 48 h post administration (Tables 4 and 5 ).
Discussion
In a recent review of genotoxicity data on aspartame, it was concluded that aspartame showed no evidence of genotoxic or mutagenic activity, which supported the conclusion of "data do not indicate a genotoxic concern" drawn by the EFSA (2013). The studies described herein, conducted using bacterial and mammalian cell systems, further support these conclusions and are in agreement with previously conducted in vitro bacterial mutation and chromosomal aberration assays and in vivo micronucleus tests (Molinary, 1978; Rencüzoğullari et al., 2004; NTP, 2005; Bandyopadhyay et al., 2008) . The bacterial reverse mutation study results indicated that aspartame did not produce a positive mutagenic response in the presence or absence of metabolic activation. The preliminary test did show 2-fold or greater increases in the number of revertants per plate in S. typhimurium TA98 with or without metabolic activation and in S. typhimurium TA1535 with metabolic activation. The findings in TA98 in the presence of S9 were of particular interest. At the three highest dose levels of 313, 1250, and 5000 μg/ plate, the increases in revertants were quite large at 10-to 12-fold then control (i.e., 250, 217, and 197 revertants at 313, 1250 , and 5000 μg/ plate, respectively, versus 20 in the controls). However, these increases were not strictly dose-dependent. A potential explanation for this finding in the preliminary assay is not readily apparent as the material tested was of high purity, was shown to be at the appropriate doses and to be stable through validated analytical assay, and no other confounding factor (e.g., inappropriate reagent use, deviation in protocol, alterations in media pH, osmolality, etc.) could be identified. Although the study was GLP-compliant, one cannot rule out possible contamination, perhaps with one of the positive controls. There is no TA100  TA1535  WP2uvrA  TA98  TA1537 S9 Mix (-) DMSO 89 ± 12.2 9 ± 1.5 17 ± 2.6 7 ± 1.7 13 ± 2.1 1.22 77 ± 3.0 8 ± 2.5 14 ± 1.2 9 ± 4.0 12 ± 3.6 4.88 78 ± 5.1 8 ± 2.5 11 ± 1.5 10 ± 2.1 11 ± 2.6 19.5 74 ± 5.5 13 ± 4.4 9 ± 1.7 6 ± 2.1 10 ± 2.5 78.1 82 ± 6.1 9 ± 2.1 11 ± 2.1 10 ± 2.1 12 ± 2.6 313 92 ± 8.7 8 ± 3.0 8 ± 3.6 14 ± 1.0 11 ± 1.7 1250 84 ± 9.3 8 ± 1.7 9 ± 3.6 8 ± 2.6 8 ± 3.0 5000 79 ± 11.0 12 ± 3.6 11 ± 0.0 10 ± 3.2 10 ± 1.5 S9 Mix (+) DMSO 105 ± 13.2 11 ± 4.4 16 ± 3.5 20 ± 7.6 12 ± 2.5 1.22 105 ± 12.0 12 ± 1.5 14 ± 4.5 21 ± 2.0 14 ± 2.1 4.88 107 ± 4.0 6 ± 1.5 21 ± 2.1 16 ± 3.8 13 ± 3.1 19.5 97 ± 16.8 9 ± 4.4 12 ± 2.6 18 ± 4.9 10 ± 1.5 78.1 102 ± 21.1 12 ± 1.5 14 ± 2.3 30 ± 2.3 11 ± 2.6 313 108 ± 20.2 25 ± 2.1 15 ± 0.6 250 ± 13.9 11 ± 2.0 1250 84 ± 15.6 28 ± 2.5 19 ± 2.1 217 ± 27.1 13 ± 4.4 5000 88 ± 19.7 32 ± 7.2 10 ± 3.1 197 ± 0.6 18 ± 7. No. of Revertants/Plate 748 ± 9.5 289 ± 7.9 921 ± 40.2 264 ± 28.5 65 ± 12.0 2AA, 2-aminoanthracene; AF-2, 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide; B[a]P, benzo[a]pyrene; DMSO, dimethyl sulfoxide; ICR-191, 2-methoxy-6-chloro-9-[3-(2-chloroethyl)-aminopropylamino]acridine.2HCl; SA, sodium azide; SD, standard deviation.
Bold indicates 2-fold or more increase in the number of revertants per plate compared to vehicle control (DMSO).
A. Otabe et al. Regulatory Toxicology and Pharmacology 103 (2019) 345-351 reason to indicate that any response specific to the presence of S9 could be responsible since aspartame does not undergo any significant cytochrome P450 metabolism (Magnuson et al., 2007) . In any case, the findings in the preliminary assay could not be reproduced either in the main mutation study or in the confirmation study even though the TA100  TA1535  WP2uvrA  TA98  TA1537 S9 Mix (-) DMSO 83 ± 2.5 6 ± 1.2 12 ± 2.9 19 ± 4.4 6 ± 0.6 78.1 NT NT NT NT NT NT 18 ± 5.0 NT NT 156 86 ± 22.1 8 ± 2.6 11 ± 4.0 19 ± 6.7 7 ± 1.0 313 85 ± 11.5 6 ± 1.2 11 ± 1.5 15 ± 2.1 5 ± 1.7 625 91 ± 6.1 7 ± 3.1 9 ± 1.2 14 ± 3.2 9 ± 2.1 1250 71 ± 7.2 5 ± 0.6 13 ± 4.2 16 ± 3.1 9 ± 2.9 2500 84 ± 12.1 6 ± 1.2 12 ± 2.6 20 ± 6.2 5 ± 2.9 5000 19 ± 5.1 S9 Mix (+) DMSO 89 ± 1.5 9 ± 2.1 11 ± 0.6 36 ± 2.3 10 ± 3.0 78.1 NT NT 7 ± 4.0 NT NT 36 ± 2.5 NT NT 156 97 ± 14.6 8 ± 1.5 13 ± 5.5 28 ± 6.0 7 ± 2.3 313 105 ± 3.5 5 ± 1.0 13 ± 3.8 29 ± 8.1 9 ± 1.5 625 108 ± 7.8 6 ± 3.2 12 ± 2.6 37 ± 9.1 6 ± 2.1 1250 107 ± 5.5 5 ± 1.0 10 ± 2.3 33 ± 6.8 11 ± 2.5 2500 106 ± 12.5 6 ± 0.6 14 ± 3.1 34 ± 0.0 9 ± 2.1 5000 7 ± 1.5 34 ± 13. maximum doses utilized were the same. Both the main and confirmatory assays showed no evidence of any increase in revertants either with or without S9, including in E. coli WP2 uvrA, thus demonstrating that aspartame does not cause base-pair substitution-induced mutation at adenosine-thymidine (AT) sites (OECD, 1997).
As can be seen in the data presented in Tables 4 and 5 , oral administration of aspartame at doses of up to 2000 mg/kg body weight had no effect on either indices of clastogenic activity (No. MNPCE/2000 PCE or MNPCE percent) or cytotoxicity to bone marrow cells (No. PCE/ 1000 erythrocytes or PCE percent) at either of the 24-or 48-h post dosing sampling points. These results are in concordance with the results of the micronucleus assay performed by the National Toxicology Program (NTP, 2005) on the peripheral blood of Fischer 344/N rats exposed to aspartame by oral gavage at either 0, 500, 1000, or 2000 mg/kg body weight for 3 times at 24-h intervals. While some evidence of bone marrow toxicity was evident at the mid-dose of 1000 mg/kg body weight (%PCE decreased from 60 to 39%), there were no increases in the incidence of micronucleated PCE. Likewise, there was no significant increases in micronucleated normochromatic erythrocytes (MNNCE) or evidence of bone marrow toxicity in Tg.AC hemizygous or Cdkn2a deficient mice or male p53 haploinsufficient mice exposed to aspartame at dietary concentrations of 0.31-5.0% (equivalent to upwards of 8000 mg/kg body weight/day) for 9 months (NTP, 2005) .
The present study was unable to replicate the reported increased incidence of micronucleated PCE in Swiss albino mice administered aspartame at doses of 455-1000 mg/kg body weight (Kamath et al., 2010) . In addition, Kamath et al. (2010) had reported that similar exposures to aspartame also induced increases in the incidence of micronucleated erythrocytes in peripheral blood and the incidence of chromosomal aberrations in bone marrow. These endpoints were not evaluated in the present study since it was conducted as a stand-alone in vivo micronucleus assay. However, EFSA (2013) notes that Kamath et al. (2010) failed to report the numbers of animals used in their studies, and for the chromosomal aberration study, did not score mitotic indices, used a colchicine treatment that was too short (1.5 hrs versus 3 hrs), and used sampling times that were the same as the in the micronucleus assay (such times are not appropriate). Similarly, the lack of effect on number and percent of PCE in the current in vivo mouse micronucleus study is in contrast to Kamath et al. (2010) who reported that the PCE:NCE ratio was changed although no data for this parameter were presented. Given the above, the results of the current in vivo mouse micronucleus assay appear to rebut the conclusions reached by Kamath et al. (2010) .
The lack of aspartame in the present in vivo micronucleus assay cannot be ascribed to potential lack of exposure of the bone marrow. Given the known pharmacokinetic and metabolic profile of aspartame following oral dosing in rats, the bone marrow would be exposed to all 3 potential hydrolysis products, including phenylalanine, aspartic acid and methanol which are generated after rapid hydrolysis of aspartame in the gastrointestinal tract prior to absorption (Stegink, 1987; Hjelle et al., 1992; Butchko et al., 2002) . For example, Hjelle et al. (1992) noted the following oral gavage administration of aspartame of Sprague-Dawley rats and CD-1 mice at doses of up to 2000 mg/kg bw/ day, pear plasma concentrations of phenylalanine and tyrosine were achieved within 1 h and returned to baseline levels with 4-8 h.
In summary, the present study provides further evidence to support the conclusion that aspartame is non-mutagenic and non-genotoxic and, in addition, the results reported herein provide first reports of negative activity of aspartame in a bacterial reverse mutation assay that included either S. typhimurium TA 102 or E. coli WP2uvrA. Also, the lack of activity of aspartame in an in vivo mouse micronucleus assay conducted to current GLP and FDA Redbook standards corroborates the initial in vivo assays conducted to support the registrations of aspartame, but which either do not completely comply with modern guidelines or which have not been published in detail in the open scientific literature.
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